Why the study?
Which drugs have evidence supporting a causal association with thrombotic microangiopathy?
Which drugs have evidence supporting a causal association with thrombotic microangiopathy?
This systematic review identifies 22 drugs with definite evidence for causing thrombotic microangiopathy, providing a critical resource for clinical evaluation.
Answers are grounded in this paper and cite their sources.
Clinicians should evaluate exposure to these 22 agents in TMA cases; extends systematic causality evidence beyond prior reports.
Many patients with syndromes of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome, have been reported to have a drug-induced etiology, and many different drugs have been suspected as a cause of TMA. We established criteria to assess the strength of evidence for a causal association of a drug with TMA and systematically searched for all published reports of drug-induced TMA. We identified 1569 articles: 604 were retrieved for review, 344 reported evaluable data for 586 individual patients, 43 reported evaluable data on 46 patient groups. Seventy-eight drugs were described; 22 had evidence supporting a definite causal association with TMA. Three drugs accounted for 61 of the 104 patient reports with definite evidence (quinine, 34; cyclosporine, 15; tacrolimus, 12). Twenty additional drugs had evidence supporting a probable association with TMA. These criteria and data can provide support for clinicians evaluating patients with suspected TMA.
No takes yet. Share an insight, caveat, or question.
Al‐Nouri et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: